Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

Genotyping and targeted sequencing of Type I EOCs frequently identifies actionable mutations. Matched treatment with MEK-based combination therapy in KRAS and/or NRAS mutant type I EOC patients is an active therapeutic strategy.